Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

Bosch, 1999, Epidemiology of primary liver cancer, Semin Liver Dis, 19, 271, 10.1055/s-2007-1007117 Llovet, 1999, Prognosis of hepatocellular carcinoma: the BCLC staging classification, Semin Liver Dis, 19, 329, 10.1055/s-2007-1007122 Bruix, 2002, Prognostic prediction and treatment strategy in hepatocellular carcinoma, Hepatology, 35, 519, 10.1053/jhep.2002.32089 Trinchet, 1997, Treatment of hepatocellular carcinoma in patients with cirrhosis, J Hepatol, 27, 756, 10.1016/S0168-8278(97)80095-5 Bruix, 2001, Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL Conference, J Hepatol, 35, 421, 10.1016/S0168-8278(01)00130-1 Lin, 1988, Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma: a randomized controlled trial, Gastroenterology, 94, 453, 10.1016/0016-5085(88)90436-2 Pelletier, 1990, A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma, J Hepatol, 11, 181, 10.1016/0168-8278(90)90110-D Madden, 1993, Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma, Gut, 34, 1598, 10.1136/gut.34.11.1598 Group d'Etude et de Traitement de Carcinome Hepatocellulaire, 1995, A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma, N Engl J Med, 332, 1256, 10.1056/NEJM199505113321903 Bruix, 1998, Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized controlled trial in a single institution, Hepatology, 27, 1578, 10.1002/hep.510270617 Pelletier, 1998, Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial, J Hepatol, 29, 129, 10.1016/S0168-8278(98)80187-6 Simonetti, 1997, Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials, Ann Oncol, 8, 117, 10.1023/A:1008285123736 Mathurin, 1998, Overview of medical treatments in unresectable hepatocellular carcinoma; an impossible meta-analysis?, Aliment Pharmacol Ther, 12, 111, 10.1046/j.1365-2036.1998.00286.x Sorensen, 1993, Performance status assessment in cancer patients: an inter-observer variability study, Br J Cancer, 67, 773, 10.1038/bjc.1993.140 Okuda, 1985, Natural history of hepatocellular carcinoma and prognosis in relation to treatment, Cancer, 56, 918, 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E Pugh, 1973, Transection of the oesophagus for bleeding oesophageal varices, Br J Surg, 60, 646, 10.1002/bjs.1800600817 Miller, 1981, Reporting results of cancer treatment, Cancer, 47, 207, 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 Whitehead, 1992 Vetter, 1991, Transcatheter oil chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: results of a Western comparative study in 60 patients, Hepatology, 13, 427, 10.1002/hep.1840130308 Venook, 1990, Chemoembolization for hepatocellular carcinoma, J Clin Oncol, 8, 1108, 10.1200/JCO.1990.8.6.1108 Mondazzi, 1994, Transarterial oil chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors, Hepatology, 19, 1115, 10.1002/hep.1840190508 Llovet, 1999, Natural history of untreated hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials, Hepatology, 29, 62, 10.1002/hep.510290145